CureDuchenne announced today that the organization is funding Dr. Susan J. Ward, a consultant to BioPharma, in partnership with Dr. James Signorovitch, Vice President at Analysis Group Inc., on a collaborative project to further the understanding of the natural history of Duchenne muscular dystrophy.
CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy that was formed by the nonprofit CureDuchenne, announced today that they are investing $1 million in Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, to advance promising research to treat heart disease associated with Duchenne muscular dystrophy.
Ì¢âÂÛÏ CureDuchenne, a national nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that its founder and CEO Debra Miller will present at the Life Science Nation Redefining Early Stage Investments conference on January 13 in San Francisco.
CureDuchenne, a national nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that they are sponsoring a $710,000 research project with Kevin Flanigan, M.D., principal investigator at the Center for Gene Therapy at Nationwide ChildrenÌ¢âÂã¢s Hospital in Columbus, Ohio, that focuses on the development of a novel therapy for deletion mutations for Duchenne muscular dystrophy.
CureDuchenne announced today that Clay Matthews of the Green Bay Packers is featured in a new Public Service Announcement to help raise awareness about Duchenne muscular dystrophy. The PSA is part of CureDuchenneÌ¢âÂã¢s ongoing efforts to raise awareness and fund research to find a cure for Duchenne, a progressive muscle-wasting disease that impacts 1 in every 3,500 boys. Boys are usually diagnosed by the age of 5, in a wheelchair by 12 and most donÌ¢âÂã¢t survive their mid-20s. Currently, there is no cure for Duchenne.
CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will continue to watch the performance of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during its acquisition of Prosensa, a biotechnology company CureDuchenne has supported at critical times.
CureDuchenne has joined #GivingTuesday, a first of its kind effort that will harness the collective power of a unique blend of partners to transform how people participate in the giving season. Following the Thanksgiving holiday and the kickoff of the holiday shopping season, #GivingTuesday inspires people to give back to charities like CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy.
CureDuchenne is encouraged about BioMarin PharmaceuticalÌ¢âÂã¢s acquisition of Prosensa and their commitment to continue the development of drugs for Duchenne muscular dystrophy. BioMarin has a deep understanding of the orphan rare disease space, experience working with regulatory authorities worldwide and a successful record of getting drugs approved.
CureDuchenne and Prosensa Holding N.V. (NASDAQ: RNA) have been selected to present at the 6th annual Partnering for Cures, November 16-18 in New York City.
